Garrett Vygantas, MD, MBA is a founding Managing Partner of Riverine Ventures, a life science and healthcare dedicated venture capital firm. Trained as a physician and an experienced entrepreneur, Garrett provides strategic direction and valuable clinical and commercial networks as a Board Member or Advisor to AEye Health, ArtiSight, Circularis, Corsair Pharma, Eliksa Therapeutics, Endotronix, Exo Imaging, HealthBridge, Inflammatix, KeifeRx and Pieces Technologies. His previous investments include Aptinyx (NASDAQ:APTX), Doctor on Demand (acq. by Grand Rounds), Health Scholars, Gauss Surgical (acq. by Stryker, NYSE: SYK) Level Ex (acq. by Brainlab), MediBeacon, Mediphage, Paradigm Cancer Diagnostics (acq. by Exact Sciences, NASDAQ:EXAS), SilverCloud (acq. by AmWell, NYSE:AMWL), Spect, Stem Inc (NYSE: STEM) and Visibly.
With over 20 years, Garrett’s expertise spans healthcare, medtech, digital health and biopharma investing and operations. He has invested on behalf of OSF Ventures, Jump Capital and Burrill & Co. He was the founding CEO of TherOptix, NewBridge Pharmaceuticals and Mitre Medical. At NewBridge, he and his team raised over $60M in financing and created $470M in nominal value. Earlier in his career Garrett helped launch Lucentis at Genentech and worked on the healthcare investment banking team at Cowen & Company. He earned his MD /MBA degree from Georgetown University and completed his residency at the University of Pennsylvania. He is a Kauffman Fellow and Mentor at the Center for Venture Education and has served on numerous not-for-profit Boards.